Inhibition of melanoma metastasis by dual-peptide PLGA NPS.
Despite the positive results observed in vitro and in vivo, clinical trials with bioactive peptides are generally hampered by their fast degradation in the biological system. Two bioactive peptides, P20 (CSSRTMHHC) and the combined peptide C (CVNHPAFACGYGHTMYYHHYQHHL) have been identified as anticancer therapeutics. Combined peptide C consists of peptide C (CVNHPAFAC), a tumor-homing peptide, conjugated to the antiangiogenic peptide HTMYYHHYQHHL with a GYG. In this work, PLGA NPs with peptide C were applied as a dual-peptide carrier for application in cancer therapy. Peptide P20 was loaded into the NPs and combined peptide C was conjugated to the NPs surface. These NPs were evaluated as a therapeutic system to treat metastatic melanoma. In vivo assays showed that P20 encapsulation in PLGA NPs enhanced its antitumor activity. The inhibitory activity of P20-PLGANPs was similar to the activity of non-encapsulated P20 in a dose fivefold higher. The inhibitory activity was even higher when P20PLGA NPs were functionalized with combined peptide C. P20PLGAPepC NPs reduced in 28% the number of lung nodules in a syngeneic model of metastatic melanoma as compared to untreated animals. Additionally to the better tumor targeting and the in situ release of P20, it is expected that the therapeutic efficiency of the dual-peptide PLGA NPs was further enhanced by a synergistic effect between P20 and combined peptide C. Our encouraging results showed that by enabling the co-delivery of two peptides and promoting tumor targeting, PLGA NPs coupled with peptide C is a promising platform for peptide-based cancer therapy.
['Arruda|Denise Costa|DC|', 'de Oliveira|Thaís Dolzany|TD|', 'Cursino|Patrícia Harume Fukuda|PHF|', 'Maia|Vera Susana Carneiro|VSC|', 'Berzaghi|Rodrigo|R|', 'Travassos|Luiz R|LR|', 'Tada|Dayane Batista|DB|http://orcid.org/0000-0002-0674-2481']
D000595:Amino Acid Sequence D000818:Animals D000970:Antineoplastic Agents D045744:Cell Line, Tumor D002470:Cell Survival D004337:Drug Carriers D004357:Drug Synergism D008175:Lung Neoplasms D008546:Melanoma, Experimental D051379:Mice D008810:Mice, Inbred C57BL D053758:Nanoparticles D010455:Peptides D000077182:Polylactic Acid-Polyglycolic Acid Copolymer D014184:Transplantation, Homologous
PLGA metastatic melanoma antitumor peptides nanoparticles